



RSV Vaccine

Study

PEARL

Participants Needed

- Physicians at **Johns Hopkins University** are working with **Sanofi Pasteur Inc.** to evaluate an **RSV (Respiratory Syncytial Virus) nasal spray vaccine** for children. This study will enroll over 6,000 children from all over the world, including the U.S.

- **RSV infection:**

- causes respiratory illness in children worldwide.
- is the leading cause of hospitalization for U.S. infants.



- **Healthy children ages 6 months to less than 22 months** are eligible for the vaccine study.

- **How can this research make a difference?**

Your child taking part in the study may help find a vaccine that works to prevent severe RSV illness. Such a vaccine may be of future benefit to babies and children in the U.S. and the rest of the world.

- **What is involved?**

Vaccine or placebo (salt solution without vaccine) administration via nasal spray, follow up visits (including swabs from the front of the nose, brief exam, and up to 4 blood draws over 2 years) by experienced nurses, online questionnaires, and phone contacts.

Principal Investigator: Ruth A. Karron, MD



For more information, contact:

Johns Hopkins University

Center for Immunization Research (CIR)

Call: (410) 502-3333 Email: RSVPed@jhu.edu



This study is voluntary. Families will receive compensation for participation.